MCID: HPT073
MIFTS: 70

Hepatitis C Virus

Categories: Genetic diseases, Rare diseases, Gastrointestinal diseases, Liver diseases, Immune diseases, Skin diseases, Infectious diseases

Aliases & Classifications for Hepatitis C Virus

MalaCards integrated aliases for Hepatitis C Virus:

Name: Hepatitis C Virus 54
Hepatitis C Virus Infection, Response to Therapy of 54 24 29
Response to Antiviral Treatment in Hepatitis C 56
Hepatitis C Virus, Response to Therapy of 54
Response to Peg/ifn-Ribavirin in Hcv 56
Hepatitis C Virus, Susceptibility to 29

Classifications:



External Ids:

OMIM 54 609532
Orphanet 56 ORPHA284102

Summaries for Hepatitis C Virus

OMIM : 54
HCV, which is principally transmitted by blood, infects about 3% of the world's population. HCV infection causes acute hepatitis, which is self-resolving in 20 to 50% of cases but does not confer permanent immunity. In 50 to 80% of cases, HCV infection becomes chronic and results in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. As a result, HCV infection is a leading killer worldwide and the most common cause of liver failure in the U.S. HCV is opportunistic in individuals infected with human immunodeficiency virus (HIV; see 609423), approximately 25% of whom are coinfected with HCV. HCV infection is also associated with cryoglobulinemia (see 123550), a B-lymphocyte proliferative disorder (Pawlotsky, 2004; Chisari (2005); Pileri et al., 1998). (609532)

MalaCards based summary : Hepatitis C Virus, also known as hepatitis c virus infection, response to therapy of, is related to recurrent hepatitis c virus induced liver disease in liver transplant recipients and hepatitis c. An important gene associated with Hepatitis C Virus is IFNL3 (Interferon Lambda 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and T cell receptor signaling pathway. The drugs Miconazole and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and homeostasis/metabolism

Related Diseases for Hepatitis C Virus

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis C Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 291)
id Related Disease Score Top Affiliating Genes
1 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.1
2 hepatitis c 11.9
3 hepatocellular carcinoma 11.5
4 hepatitis 11.3
5 ifnl3-related altered drug metabolism 11.0
6 hepadnavirus infection 11.0 GPT HLA-DRB1 IFNG
7 fibrillary glomerulonephritis 10.9
8 immunotactoid glomerulopathy 10.9
9 immunotactoid or fibrillary glomerulopathy 10.9
10 isthmus cancer 10.9 CLDN1 GPT HLA-DRB1
11 cutaneous fibrous histiocytoma 10.9 EGFR GPT IFNG
12 anthracosilicosis 10.9 HLA-DRB1 IFNG
13 hereditary ataxia 10.9 CD81 CLDN1 CLDN6 GPT IFNL4 PSMA7
14 reese retinal dysplasia 10.9 EGFR HLA-DRB1
15 hereditary hemorrhagic telangiectasia 10.8 DDX3X GPT IFNG PIK3CA PSMA7
16 mosaic trisomy 1 10.8 HLA-DRB1 IFNG
17 eczematous dermatitis of eyelid 10.8 CD81 CLDN1 CLDN6 CLEC4M GPT HM13
18 stenosis of lacrimal punctum 10.7 EGFR PIK3CA
19 cryoglobulinemia 10.7
20 chorioangioma 10.6 EGFR PIK3CA
21 liver disease 10.5
22 glomerulonephritis 10.5
23 hepatitis b 10.4
24 gingivitis 10.4 IFNG PIK3CA
25 lymphoma 10.4
26 membranoproliferative glomerulonephritis 10.4
27 porphyria cutanea tarda 10.4
28 porphyria 10.4
29 vasculitis 10.3
30 liver cirrhosis 10.3
31 lichen planus 10.2
32 oral lichen planus 10.2
33 b-cell lymphomas 10.1
34 carotid artery dissection 10.1 CCR5 CD81 CLEC4M GPT IFNG
35 type ii mixed cryoglobulinemia 10.1
36 arthritis 10.1
37 thyroiditis 10.0
38 leukemia 10.0
39 thalassemia 10.0
40 hepatitis d 10.0
41 kidney disease 10.0
42 alcoholic hepatitis 10.0
43 thrombocytopenia 10.0
44 hepatitis a 10.0
45 viral hepatitis 10.0
46 hemophilia 10.0
47 cataract 29, coralliform 10.0 CCR5 CLEC4M DDX3X IFNG PSMA7
48 hemochromatosis 10.0
49 diffuse large b-cell lymphoma 10.0
50 proliferative glomerulonephritis 10.0

Graphical network of the top 20 diseases related to Hepatitis C Virus:



Diseases related to Hepatitis C Virus

Symptoms & Phenotypes for Hepatitis C Virus

Clinical features from OMIM:

609532

GenomeRNAi Phenotypes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 9.17 CD81 CLDN1 DDX3X GPT HM13 PI4KA

MGI Mouse Phenotypes related to Hepatitis C Virus:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.9 CCR5 CD81 CLDN1 CLEC4M DDX3X EGFR
2 immune system MP:0005387 9.7 IFNG IFNL3 PI4KA PIK3CA PTPRC SCARB1
3 no phenotypic analysis MP:0003012 9.23 CCR5 CLDN6 EGFR IFNG PI4KA PIK3CA

Drugs & Therapeutics for Hepatitis C Virus

Drugs for Hepatitis C Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 564)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
3
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
4
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
5
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
6
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
7
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
8
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
9
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
10
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 99210-65-8, 215647-85-1
11
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
12
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
13
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 143491-57-0 60877
14
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
15
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
16
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
17
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
18
Insulin Glargine Approved Phase 4 160337-95-1
19
Insulin-glulisine Approved Phase 4 207748-29-6
20
Zinc Approved Phase 4 7440-66-6 32051 23994
21
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3 142217-69-4 153941
22
Thrombin Approved Phase 4,Phase 3,Phase 1
23
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1 923604-59-5 66576988
24
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1190307-88-0 45375808
25
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
26
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
27
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1256388-51-8 67505836
28
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 154598-52-4 64139
29
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 134678-17-4 60825
30
Zidovudine Approved Phase 4,Phase 1,Phase 2 30516-87-1 35370
31
Interferon alfacon-1 Approved Phase 4,Phase 3,Phase 2 118390-30-0 9554198
32
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 1 376348-65-1 3002977
33
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 192725-17-0 92727
34
Nevirapine Approved Phase 4 129618-40-2 4463
35
Rifaximin Approved, Investigational Phase 4,Phase 2 80621-81-4 6436173
36
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
37
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
38
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
39
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
40
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
41
Cobicistat Approved Phase 4,Phase 3,Phase 1 1004316-88-4
42
Daclizumab Approved, Investigational Phase 4 152923-56-3
43
Iron Approved Phase 4,Phase 2 7439-89-6 23925
44
Losartan Approved Phase 4 114798-26-4 3961
45
Nelfinavir Approved Phase 4 159989-64-7 64143
46
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
47
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
48
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
49
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
50
chloroquine Approved, Vet_approved Phase 4,Phase 1 54-05-7 2719

Interventional clinical trials:

(show top 50) (show all 2129)

id Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
3 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
4 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
5 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
6 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
7 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
8 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
9 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
10 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
11 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
12 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
13 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
14 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
15 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
16 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
17 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
18 Ribavirin, Its Dosing Regime Unknown status NCT00484328 Phase 4 Ribavirin
19 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
20 Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
21 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
22 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
23 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
24 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
25 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
26 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
27 Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel) Unknown status NCT01230931 Phase 4
28 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
29 Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
30 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
31 Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 Completed NCT00143000 Phase 4 Peginterferon alfa-2a 40KD and Ribavirin
32 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation Completed NCT00821587 Phase 4 Cyclosporine;Tacrolimus
33 A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir Completed NCT02103699 Phase 4 No intervention
34 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
35 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
36 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed NCT01097395 Phase 4 ribavirin
37 Treatment of Acute Hepatitis C Virus in HIV Co-Infection Completed NCT00845676 Phase 4 Pegylated interferon alfa-2a + Ribavirin
38 Australian Trial in Acute Hepatitis C Completed NCT00192569 Phase 4 Pegylated Interferon alfa 2a;Ribavirin (HIV conifected patients only)
39 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Completed NCT00938860 Phase 4 cyclosporin (Neoral);tacrolimus (Prograf)
40 Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation. Completed NCT00383864 Phase 4 Pegylated interferon and ribavirin
41 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. Completed NCT00545233 Phase 4 peginterferon alfa-2a [Pegasys];ribavirin [Copegus];Pioglitazone
42 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) Completed NCT02768961 Phase 4 sofosbuvir;ledipasvir
43 Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users Completed NCT00194480 Phase 4 Pegylated Interferon
44 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
45 PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. Completed NCT00087633 Phase 4 peginterferon alfa-2a [Pegasys];Copegus
46 The SIM-SOF Trial for Hepatitis C Completed NCT02168361 Phase 4 Pegylated Interferon alfa-2b;Simeprevir;Ribavirin;Sofosbuvir
47 Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy Completed NCT01120795 Phase 4 Pegylated interferon and ribavirin;Pegylated interferon and ribavirin
48 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
49 Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C Completed NCT00910975 Phase 4 Peg-interferon-alfa2a (Pegasys);Ribavirin (Copegus)
50 Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients Completed NCT00993122 Phase 4 ribavirin pre-treatment

Search NIH Clinical Center for Hepatitis C Virus

Genetic Tests for Hepatitis C Virus

Genetic tests related to Hepatitis C Virus:

id Genetic test Affiliating Genes
1 Hepatitis C Virus, Susceptibility to 29
2 Hepatitis C Virus Infection, Response to Therapy of 29 24 IFNL3

Anatomical Context for Hepatitis C Virus

MalaCards organs/tissues related to Hepatitis C Virus:

39
Liver, Testes, Kidney, T Cells, B Cells, Bone, Heart

Publications for Hepatitis C Virus

Articles related to Hepatitis C Virus:

(show top 50) (show all 3622)
id Title Authors Year
1
Development of proteinuria and focal segmental glomerulosclerosis during direct acting antiviral therapy for hepatitis C virus infection (HEP-16-2474.R1). ( 28211090 )
2017
2
Polymorphisms of chemokine receptor genes and clearance of hepatitis C virus infection in Chinese population. ( 28456591 )
2017
3
Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3' variants. ( 28082397 )
2017
4
Hepatitis C virus status in hemodialysis patients in Menoufia Government, Egypt, five years apart: Do we have any improvement? ( 28937073 )
2017
5
Retinoid BMS411 (4-{[(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl) carbonyl] amino} benzoic acid), a potential inhibitor of NS5A protein of hepatitis C virus, a candidate for combined therapy of hepatitis C infection. ( 28523927 )
2017
6
Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant. ( 28083718 )
2017
7
Diskitis, Osteomyelitis, Spinal Epidural Abscess, Meningitis, and Endocarditis Following Sacroiliac Joint Injection for the Treatment of Low-Back Pain in a Patient on Therapy for Hepatitis C Virus. ( 28492440 )
2017
8
Spontaneous clearance of chronic hepatitis C virus infection in HIV-positive patients, southeastern France. ( 28526244 )
2017
9
Community-based molecular epidemiology study of hepatitis C virus infection in injection drug users. ( 28943522 )
2017
10
Dermatomyositis revealing both a metastatic linitis plastica and hepatitis C virus infection. ( 28731019 )
2017
11
Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. ( 28516201 )
2017
12
Magnetic resonance imaging in central nervous system vasculitis in a patient affected by crioglobulin-negative hepatitis C virus infection: A likely correlation. ( 28735554 )
2017
13
Primary Care Perspectives on Hepatitis C Virus Screening, Diagnosis and Linking Patients to Appropriate Care. ( 28087291 )
2017
14
Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature. ( 28529936 )
2017
15
Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection. ( 28127569 )
2017
16
Hepatitis C virus NS4B protein induces epithelial-mesenchymal transition by upregulation of Snail. ( 28431572 )
2017
17
Hepatitis C Virus E1 protein promotes cell migration and invasion by modulating cellular metastasis suppressor Nm23-H1. ( 28376369 )
2017
18
Association of Toll-Like Receptor 3 and Toll-Like Receptor 9 Single Nucleotide Polymorphisms with Hepatitis C Virus Infection and Hepatic Fibrosis in Egyptian Patients. ( 28093541 )
2017
19
Direct-acting antivirals for hepatitis C virus induce a rapid clinical and biochemical remission of porphyria cutanea tarda. ( 28369802 )
2017
20
Extracellular Interactions between Hepatitis C Virus and Secreted Apolipoprotein E. ( 28539442 )
2017
21
Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. ( 28514954 )
2017
22
T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection. ( 27809352 )
2017
23
Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents. ( 28529212 )
2017
24
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. ( 28948366 )
2017
25
Cellular DEAD-box RNA helicase DDX6 modulates interaction of miR-122 with the 5' untranslated region of hepatitis C virus RNA. ( 28456022 )
2017
26
Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells. ( 28935193 )
2017
27
Pityriasis rosea in a patient with retrovirus infection and a history of syphilis and positive results of infection with hepatitis A virus, hepatitis B virus and hepatitis C virus. ( 28670260 )
2017
28
Combination Therapy with Ombitasvir/Paritaprevir/Ritonavir for Dialysis Patients Infected with Hepatitis C Virus: A Prospective Multi-Institutional Study. ( 28090038 )
2017
29
Comparison of Abbott RealTime genotype II, GeneMatrix restriction fragment mass polymorphism, and Sysmex HISCL HCV Gr assays for hepatitis C virus genotyping. ( 28076298 )
2017
30
microRNA-122 target sites in the hepatitis C virus RNA NS5B coding region and 3' untranslated region: function in replication and influence of RNA secondary structure. ( 27677491 )
2017
31
Direct-acting antiviral drugs against hepatitis C virus in renal transplant recipients: Is it the dawn of an interferon-free Era? ( 28937081 )
2017
32
Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations. ( 28512229 )
2017
33
Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis. ( 28947525 )
2017
34
Highly Successful Hepatitis C Virus (HCV) Treatment Outcomes in Human Immunodeficiency Virus/HCV-Coinfected Patients at a Large, Urban, Ryan White Clinic. ( 28534036 )
2017
35
Five Near full-length Hepatitis C virus sequences were isolated from HIV coinfected IDUs of China. ( 28075146 )
2017
36
Hepatitis C virus triggers Golgi fragmentation and autophagy through the immunity-related GTPase M. ( 28389568 )
2017
37
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir A+ Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. ( 28948180 )
2017
38
Hepatitis C virus-associated cryoglobulinemia with membrano-proliferative glomerulonephritis treated with prednisolone and interferon: A case report. ( 28810602 )
2017
39
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. ( 28453396 )
2017
40
Hepatitis C virus lipoviroparticles (HCV-LVP) assemble in the endoplasmic reticulum (ER) and bud off from the ER to Golgi in COPII vesicles. ( 28515296 )
2017
41
The Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor. ( 28947470 )
2017
42
Analysis of Hepatitis C Virus Particle Heterogeneity in Immunodeficient Human Liver Chimeric fah-/- Mice. ( 28936471 )
2017
43
Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report. ( 28356063 )
2017
44
Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir. ( 28089092 )
2017
45
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. ( 28535298 )
2017
46
A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant. ( 28509128 )
2017
47
Single-Center Experience in Pre-transplant Hepatitis C Virus (HCV) Treatment Among Living Donor Liver Transplant Candidates: Bridging the Direct-Acting Antivirals (DAA). ( 28935852 )
2017
48
NS5B Promotes Degradation of the NORE1A Tumor Suppressor to Facilitate Hepatitis C Virus Replication. ( 28090674 )
2017
49
Prevalence and correlates of hepatitis C virus-associated inflammatory arthritis in a population-based cohort. ( 28532574 )
2017
50
A preliminary investigation on single nucleotide polymorphism rs2287622 of bile salt export pump gene in patients with chronic hepatitis C virus infection in Hunan, China. ( 28292275 )
2017

Variations for Hepatitis C Virus

ClinVar genetic disease variations for Hepatitis C Virus:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PTPRC PTPRC, 77C-G single nucleotide variant risk factor

Expression for Hepatitis C Virus

LifeMap Discovery
Genes differentially expressed in tissues of Hepatitis C Virus patients vs. healthy controls: 35
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL10 chemokine (C-X-C motif) ligand 10 Liver + 4.26 0.000
2 CXCL11 chemokine (C-X-C motif) ligand 11 Liver + 3.57 0.000
3 LOC553137 uncharacterized LOC553137 Liver - 3.21 0.000
4 CXCL9 chemokine (C-X-C motif) ligand 9 Liver + 3.07 0.000
Search GEO for disease gene expression data for Hepatitis C Virus.

Pathways for Hepatitis C Virus

GO Terms for Hepatitis C Virus

Cellular components related to Hepatitis C Virus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 CCR5 HLA-DRB1 IFNG PTPRC
2 cell surface GO:0009986 9.1 CCR5 EGFR HLA-DRB1 HM13 PTPRC SCARB1

Biological processes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.76 CLEC4M DDX3X IFNL3 IFNL4
2 defense response to virus GO:0051607 9.67 IFNG IFNL3 IFNL4 PTPRC
3 phosphatidylinositol phosphorylation GO:0046854 9.65 EGFR PI4KA PIK3CA
4 cell surface receptor signaling pathway GO:0007166 9.65 CCR5 CD81 EGFR IFNG PTPRC
5 T cell receptor signaling pathway GO:0050852 9.55 HLA-DRB1 IFNG PIK3CA PSMA7 PTPRC
6 antigen processing and presentation GO:0019882 9.5 CLEC4M HLA-DRB1 IFNG
7 positive regulation of immune response GO:0050778 9.43 IFNL3 IFNL4
8 viral entry into host cell GO:0046718 9.43 CD81 CLDN1 CLDN6 CLEC4M HLA-DRB1 SCARB1
9 regulation of T cell activation GO:0050863 9.4 IFNL3 IFNL4
10 viral process GO:0016032 9.32 CCR5 CD81 CLDN1 CLDN6 CLEC4M DDX3X

Molecular functions related to Hepatitis C Virus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.17 CCR5 CD81 CLDN1 CLDN6 CLEC4M HLA-DRB1
2 MHC class II protein complex binding GO:0023026 8.96 CD81 HLA-DRB1

Sources for Hepatitis C Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....